Rates of Disease Progression according to Initial Highly Active Antiretroviral Therapy Regimen: A Collaborative Analysis of 12 Prospective Cohort Studies
Open Access
- 1 September 2006
- journal article
- conference paper
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 194 (5) , 612-622
- https://doi.org/10.1086/506362
Abstract
BackgroundNo large clinical end-point trials have been conducted comparing regimens among human immunodeficiency virus type 1–positive persons starting antiretroviral therapy. We examined clinical progression according to initial regimen in the Antiretroviral Therapy Cohort Collaboration, which is based on 12 European and North American cohort studiesThis publication has 8 references indexed in Scilit:
- Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1PLoS Medicine, 2004
- Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapyStatistics in Medicine, 2004
- Outpatient pharmacy care and HIV viral load response among patients on HAARTAIDS Care, 2004
- Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trialsBMJ, 2004
- Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studiesAIDS, 2003
- Measuring inconsistency in meta-analysesBMJ, 2003
- A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsAIDS, 2003
- Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?AIDS, 2003